期刊
KIDNEY INTERNATIONAL
卷 83, 期 3, 页码 343-345出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/ki.2012.412
关键词
-
Multiple-relapsing minimal-change disease (MCD) often requires exposure to potentially toxic agents in an attempt to achieve a lasting remission of nephrotic syndrome. Munyentwali and co-workers describe an experience using rituximab in adults with multiple-relapsing MCD that supports both efficacy and safety of this agent. However, the optimal dosing regimen and mechanism of action remain unclear. Thus, randomized controlled trials are warranted in both adults and children to better define the role of rituximab in multiple-relapsing MCD. Kidney International (2013) 83, 343-345. doi:10.1038/ki.2012.412
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据